Opus Genetics (NASDAQ:IRD – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.01, Zacks reports. Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 59.72%. The business had revenue of $3.87 million during the quarter, compared to the consensus estimate of $1.17 million.
Opus Genetics Stock Performance
IRD traded down $0.06 during trading on Wednesday, hitting $1.08. 204,290 shares of the stock traded hands, compared to its average volume of 170,733. Opus Genetics has a twelve month low of $1.07 and a twelve month high of $3.40.
Analyst Ratings Changes
Separately, HC Wainwright assumed coverage on shares of Opus Genetics in a research report on Wednesday. They set a “buy” rating and a $8.00 price objective for the company.
Opus Genetics Company Profile
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
Read More
- Five stocks we like better than Opus Genetics
- The How and Why of Investing in Gold Stocks
- Rocket Lab is the Right Stock for the Right Time
- Where Do I Find 52-Week Highs and Lows?
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
